Navigation Links
Spectral announces second quarter 2009 results
Date:8/13/2009

loss for the period (701) (419) (1,105) (867) Deficit - Beginning of period (4,593) (3,135) (4,189) (2,687) ----------------------- ----------------------- Deficit - End of period (5,294) (3,554) (5,294) (3,554) ----------------------- ----------------------- ----------------------- ----------------------- Basic and diluted loss per common share (0.03) (0.02) (0.05) (0.04) ----------------------- ----------------------- ----------------------- ----------------------- Weighted average number of common shares outstanding 24,118,424 24,118,424 24,118,424 24,118,424 ----------------------- ----------------------- ----------------------- ----------------------- Spectral Diagnostics Inc. Statements of Cash Flows - unaudited For the six months ended June 30, 2009 and 2008 ------------------------------------------------------------------------- (in thousands of dollars) 3 Months Ended 6 Months Ended June 30 June 30 2009 2008 2009 2008 $ $ $ $ Cash provided by (used in) Operating activities Loss and comprehensive loss for the period (701) (419) (1,105) (867) Items not affecting cash Amortization 159 164 323 318 Amortization of commercial instruments included in cost of sales 22 7
'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
2. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
3. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. Spectral appoints Anthony Bihl to Board of Directors
6. Spectral announces 2007 financial results
7. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
8. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
9. Spectral and Toray expand collaboration to include new geographic territories
10. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
11. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
(Date:4/16/2015)... , April 16, 2015 /PRNewswire/ - Portage Biotech ... Canadian Securities Exchange: PBT.U), is pleased to announce that ... Show on April 25, 2015 to be held in ... Gregory Bailey and Mr. James Mellon ... and an update on the key programs at its ...
(Date:4/16/2015)... ChemRar High Tech ... R&D group, and Lancet, Russian Distribution Company, ... commercialization of new medicines in ... stimulate the innovative development of the Russian ... ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , Through ...
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... COLUMBIA, Md., Sept. 13 Martek Biosciences,Corporation (Nasdaq: ... presenting at the,upcoming UBS Global Life Sciences Conference ... September 24-27, 2007 at the Grand Hyatt in ... on Tuesday, September 25th at,3:00 p.m. Eastern Time. ...
... 13 Vet-Stem, Inc., the global leader,in regenerative ... to the Central Veterinary Research Laboratory (CVRL) of,Dubai ... the laboratory to,offer adipose- derived stem cell services ... ruler of Dubai and Prime Minister of the ...
... Together Thought Leaders,in Life Sciences and Clinical Diagnostics ... Netherlands, Sept. 13 Luminex,Corporation (Nasdaq: LMNX ... the agenda for Planet xMAP Europe 2007, the ... will be,held 2-3 October at the Berlage,s Exchange ...
Cached Biology Technology:Vet-Stem and Central Veterinary Research Labs of Dubai Sign Exclusive License 2Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium 2Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium 3
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
(Date:4/2/2015)... 2015 Fingerprint Cards (FPC) has ... from the distributor World Peace Industrial Group (WPI), part ... although the major part of the shipments will take ... by smartphone manufacturers in China . ... the communicated revenue guidance of + 1 000 MSEK for ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... living on the Port Valdez seafloor to stabilize after ... at the University of Alaska Fairbanks. "The earthquake, ... tsunami waves that followed, impacted every marine community in ... professor at the UAF School of Fisheries and Ocean ...
... YORK (April 24, 2011) -- A team of scientists ... Weill Cornell Medical College has shed light on the ... the cell membranes of neurons that modulate the transfer ... The research, published today in the journal Nature, ...
... ,Chicago, IL Stephen Maturo, MD, of Boston, MA, ... Award for outstanding achievement in the field of pediatric ... (EMG) in Children with Vocal Fold Mobility: Results of ... 29 May 1, 2011, in Chicago, IL. The ...
Cached Biology News:Port Valdez invertebrates stabilized 26 years after quake 2Molecular movements of neural transporters unveiled 2Molecular movements of neural transporters unveiled 3Molecular movements of neural transporters unveiled 4Molecular movements of neural transporters unveiled 5Stephen Maturo, M.D., ear, nose and throat specialist, receives Charles Ferguson Award 2
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
...
Biology Products: